亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Time of day of neoadjuvant immune checkpoint inhibitor administration is associated with survival but not pathological response in resectable stage III–IV melanoma: A retrospective cohort study

医学 回顾性队列研究 肿瘤科 内科学 病态的 阶段(地层学) 免疫检查点 队列 免疫系统 队列研究 总体生存率 完全响应 新辅助治疗 遗产管理(遗嘱认证法) 化疗 生存分析
作者
Axel Nelson,Safa Alghaib,Karl Björkström,Karolin Isaksson,Ellen Krabbe,Sophie Orme,Måns Kadefors,Mikael Wallander,Sara Bjursten,Gustav Jörgen Ullenhag,Ana Carneiro,Hildur Helgadóttir,Lars Ny,Roger Olofsson Bagge
出处
期刊:European Journal of Cancer [Elsevier BV]
卷期号:243: 116833-116833 被引量:2
标识
DOI:10.1016/j.ejca.2026.116833
摘要

BACKGROUND: Circadian rhythms regulate immune cell trafficking and function, and emerging clinical data suggest that the timing of immune checkpoint inhibitor (ICI) administration may influence efficacy. In advanced disease, later-day administration has been associated with inferior outcomes. Whether this applies to neoadjuvant ICI in resectable stage III-IV melanoma is unknown. METHODS: This retrospective cohort study included patients with resectable stage III-IV cutaneous melanoma treated with neoadjuvant ICI at four Swedish academic centers. Patients were categorized by timing of ICI across two infusions (morning, both <12:00; afternoon, both ≥12:00; mixed, one <12:00 and one ≥12:00). The primary endpoint was major pathological response. Secondary endpoints were event-free (EFS), distant metastasis-free (DMFS), melanoma-specific (MSS), and overall survival (OS). Associations were assessed using logistic regression and Cox models. RESULTS: A total of 265 patients were included (morning, n = 94; mixed, n = 96; afternoon, n = 75). Major pathological response rates were similar across groups (morning 47%, mixed 44%, afternoon 40%; p = 0.68). After a median follow-up of 17.4 months, morning administration was associated with a lower hazard of events across survival endpoints versus afternoon, including DMFS (HR 0.47, 95% CI 0.23-0.96), MSS (HR 0.18, 95% CI 0.04-0.71), and OS (HR 0.13, 95% CI 0.04-0.50) but not EFS (HR 0.58, 95% CI 0.31-1.08), compared with afternoon administration. Associations remained after adjustment for pathological response. CONCLUSIONS: Time of day of neoadjuvant ICI administration was not associated with pathological response. However, afternoon administration was associated with worse survival outcomes. These findings suggest treatment timing may influence long-term outcomes, although prospective validation is needed.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Moon完成签到 ,获得积分10
2秒前
天真的乐驹完成签到 ,获得积分10
6秒前
李健的小迷弟的应助被郦稀采纳,获得10
6秒前
Moon关注了科研通微信公众号
6秒前
7秒前
乐康完成签到,获得积分10
7秒前
10秒前
复杂惜珊完成签到,获得积分10
17秒前
cx完成签到,获得积分10
22秒前
机灵伟诚完成签到,获得积分10
22秒前
学霸业的应助被纯情的阁采纳,获得10
24秒前
极限001的应助被纯情的阁采纳,获得50
24秒前
Maestro_S的应助被纯情的阁采纳,获得10
24秒前
Nikkie2411的应助被纯情的阁采纳,获得10
24秒前
27秒前
28秒前
369ninja的应助被科研通管家采纳,获得10
30秒前
丘比特的应助被科研通管家采纳,获得10
30秒前
手打鱼丸完成签到 ,获得积分10
30秒前
30秒前
完美世界的应助被科研通管家采纳,获得10
30秒前
莫名乐乐完成签到,获得积分10
30秒前
FashionBoy的应助被科研通管家采纳,获得10
30秒前
SciGPT的应助被科研通管家采纳,获得10
30秒前
Akim的应助被纯情的阁采纳,获得10
30秒前
null的应助被科研通管家采纳,获得10
30秒前
31秒前
隐形曼青的应助被纯情的阁采纳,获得10
31秒前
null的应助被科研通管家采纳,获得10
31秒前
wanci的应助被科研通管家采纳,获得30
31秒前
大个的应助被纯情的阁采纳,获得30
31秒前
31秒前
学霸业的应助被纯情的阁采纳,获得10
31秒前
null的应助被科研通管家采纳,获得10
31秒前
祟祟发布了新的文献求助20
31秒前
研友_VZG7GZ的应助被纯情的阁采纳,获得30
31秒前
极限001的应助被纯情的阁采纳,获得50
31秒前
木十四完成签到 ,获得积分10
33秒前
牛马大帝发布了新的文献求助10
33秒前
爆米花的应助被椰子云采纳,获得10
34秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158598
求助须知:如何正确求助?哪些是违规求助? 9554358
关于积分的说明 21719087
捐赠科研通 7748128
什么是DOI,文献DOI怎么找? 3427032
关于科研通互助平台的介绍 2551902
邀请新用户注册赠送积分活动 2471277